Company Profile

Shandong Duyi Pharmaceutical Co., Ltd., located in Rencheng District, Jining City, Shandong Province, is a pharmaceutical enterprise integrating Chinese patent medicine, biological products and health care products, with convenient transportation and superior geographical location. The company has carried out overall planning and design in accordance with GMP requirements, with a reasonable layout, and purchased advanced pharmaceutical equipment and testing instruments both domestically and internationally, ensuring the quality of the products. Since its establishment, the company has always adhered to the development concept of "Science and technology are productivity", continuously accelerated the pace of technological innovation and independent brand construction, and created the core competitiveness of the enterprise.

Taking the modernization of traditional Chinese medicine as the breakthrough point, the company is committed to the modernization development and research of Chinese patent medicine. Products including tablet, granule preparation, injection, oral liquid, powder, capsule preparation and other several series of dozens of varieties have been produced.

The company advocates a people-oriented corporate culture and a harmonious and upward employment mechanism, focuses on the development and management of human resources, and continuously introduces engineering and technical talents from major pharmaceutical universities and industries. The company maintains good cooperative development relationships with several domestic research institutions, and its scientific research center has been rated as a provincial-level technology development center, providing strong technical support for the development of the enterprise.

Looking towards the future, the company will take quality as the center, market as the orientation, production as the basis, and new product development as the driving force. We will promote the continuous development of enterprises through advanced management models, further implement capital operation strategies in the future, continuously expand financing channels, and gradually achieve the goal of "Product globalization, capitalization, industrial informatization, and greater value-added".